Arrowhead Pharmaceuticals Inc ARWR:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
24.77UNCH (UNCH)
Volume
25,577,808
Close
24.77quote price arrow down-0.23 (-0.92%)
Volume
710,610
52 week range
20.67 - 39.83
Loading...
  • Open24.95
  • Day High25.64
  • Day Low24.57
  • Prev Close25.00
  • 52 Week High39.83
  • 52 Week High Date01/10/24
  • 52 Week Low20.67
  • 52 Week Low Date12/01/23

Key Stats

  • Market Cap3.076B
  • Shares Out124.20M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.96
  • YTD % Change-18.3

KEY STATS

  • Open24.95
  • Day High25.64
  • Day Low24.57
  • Prev Close25.00
  • 52 Week High39.83
  • 52 Week High Date01/10/24
  • 52 Week Low20.67
  • 52 Week Low Date12/01/23
  • Market Cap3.076B
  • Shares Out124.20M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.96
  • YTD % Change-18.3

RATIOS/PROFITABILITY

  • EPS (TTM)-4.24
  • P/E (TTM)-5.84
  • Fwd P/E (NTM)-11.71
  • EBITDA (TTM)-457.822M
  • ROE (TTM)-101.18%
  • Revenue (TTM)35.473M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,346.13%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/05/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Arrowhead Pharmaceuticals Inc

 

Profile

MORE
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting...
Douglass Given M.D., Ph.D.
Independent Chairman of the Board
Christopher Anzalone Ph.D.
President, Chief Executive Officer, Director
Patrick O'Brien J.D.
Chief Operating Officer, General Counsel, Company Secretary
Kenneth Myszkowski
Chief Financial Officer
Address
177 E Colorado Blvd, Suite 700
Pasadena, CA
91105
United States

Top Peers

SYMBOLLASTCHG%CHG
MRUS
Merus NV
43.91-1.11-2.47%
CLDX
Celldex Therapeutics Inc
38.21-1.73-4.33%
MLTX
MoonLake Immunotherapeutics
39.75-1.11-2.72%
APGE
Apogee Therapeutics Inc
50.31-3.44-6.40%
JANX
Janux Therapeutics Inc
47.10-0.41-0.86%